Phio announces addition of three clinical trial sites for Phase 1b study

Phio Pharmaceuticals announced the addition of three clinical trial sites for its Phase 1b study of PH-762. PH-762 is an INTASYL compound that silences PD-1, a protein that inhibits T cells’ ability to kill cancer cells. The Phase 1b trial is a non-comparative study of neoadjuvant monotherapy using PH-762 in adult patients with cutaneous squamous cell carcinoma, melanoma, or Merkel cell carcinoma. The study is designed to evaluate the safety and tolerability of neoadjuvant use of intratumorally injected PH-762, assess the tumor response, and determine the dose or dose range for continued study of PH-762 in patients with cutaneous squamous cell carcinoma, melanoma, or Merkel cell carcinoma. “We are delighted to be able to include these sites, all of whom have an interest in immuno-oncology and an exceptional reputation in conducting trials in skin cancer. Additionally, their inclusion expands our geographic reach facilitating broader patient inclusion in the clinical trial,” said Robert Bitterman, CEO of Phio Pharmaceuticals.